Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pregnyl® in High-Risk or Refractory Acute Graft-Versus-Host Disease
NCT02525029Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Mar 2016
- Primary completion
- May 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of human chorionic gonadotropin in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Masonic Cancer Center. Started Mar 2016; status: completed.
02
Drugs
human chorionic gonadotropin
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT02525029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02525029.